Xenon Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Xenon Pharmaceuticals han disminuido a una tasa media anual de -34.7%, mientras que en la industria Biotechs los beneficios crecieron en un 36.2% anualmente. Los ingresos han ido disminuyendo a una tasa media de 50.4% al año.
Información clave
-34.67%
Tasa de crecimiento de los beneficios
-24.51%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.04% |
| Tasa de crecimiento de los ingresos | -50.37% |
| Rentabilidad financiera | -28.64% |
| Margen neto | n/a |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Jun 26
XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter
The updated analyst price target for Xenon Pharmaceuticals has moved from $58.58 to $63.00, as analysts factor in refreshed models and recent Street research that includes higher targets from firms such as JPMorgan and Wells Fargo, alongside a modest trim from Needham. Analyst Commentary Recent Street research on Xenon Pharmaceuticals shows a mixed tone, with some large firms, including JPMorgan, lifting price targets while other bearish analysts trim expectations.Seeking Alpha • Apr 22
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Summary Xenon Pharmaceuticals Inc.’s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner’s differentiated Kv7 mechanism, once-daily dosing, and no-titration profile may help its future adoption, especially for polytreated epilepsy patients. XENE plans its NDA submission in Q3 2026, which would be a key transition toward potential commercialization and revenues. XENE also has ample liquidity after recent equity raises, which I think materially reduces its risk despite the ongoing cash burn. I believe XENE stock’s valuation already reflects its success to some extent. So, further upside likely depends on new indications and commercial execution. Read the full article on Seeking AlphaNueva narrativa • Mar 27
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel based therapies for epilepsy, depression, bipolar disorder and pain. What are the underlying business or industry changes driving this perspective?
Nueva narrativa • Mar 09
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Artículo de análisis • Oct 01
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Apr 18
Xenon- A Later Stage Story
Summary Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications. Despite broader biotech market challenges, Xenon's strong efficacy and safety data position it well, with significant interest from major pharma in neurology and neuropsychiatry. Read the full article on Seeking AlphaSeeking Alpha • Jan 16
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Summary Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time. I also believe its late-stage IP is diversified with ion channel modulators for pain and other neurological conditions. So it’s not overly exposed to Azetukalner. I concede that XENE has a premium valuation, but I think 2025 will provide significant clinical data that could justify a “Buy” rating at these levels. Read the full article on Seeking AlphaSeeking Alpha • Aug 09
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Summary Xenon Pharmaceuticals is a Canadian biopharma company targeting neurological diseases with a focus on ion channel-blocking technology. The clinical stage asset, azetukalner, is in late stage development for epilepsy and Major Depressive Disorder, showing promising results in reducing seizure frequency. Despite a history of failures and low trading volume, Xenon has a strong cash position and upcoming catalysts in phase 3 trials for their lead asset. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Summary Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. The company has experienced "setbacks" in recent trials, but its primary drug candidate, XEN1101, shows significant potential for treating epilepsy. Xenon has initiated Phase 3 clinical trials for XEN1101 and has received myriad positive ratings from analysts, but the stock may be vulnerable to profit-taking. An analysis around Xenon Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 19
Xenon started at outperform at Raymond James on experimental epilepsy drug
Raymond James has initiated Xenon Pharmaceuticals (NASDAQ:XENE) with an outperform rating citing the blockbuster potential of XEN1101, currently in phase 2 for epilepsy. The firm has a $52 price target (~46% upside based on Tuesday's close). Analyst Danielle Brill is confident that XEN1101 will be successful given its strong phase 2 results. She predicted a greater than $1B peak sales opportunity. Xenon (XENE) plans to initiate two identical phase 3 clinical trials. She noted that the the candidate, which is also under development for major depressive disorder, could further benefit from proof-of-concept data in that indication expected in 2023. Brill added that the company's pipeline also presents growth opportunities with XEN496 in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE), and NBI-921352 for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). XEN1101 is also under investigation for primary generic clonic tonic seizures (PGTCS). In August, BofA started Xenon (XENE) with a buy rating also citing the blockbuster potential of XEN1101 for epilepsy.Seeking Alpha • Sep 06
Putting Xenon Pharmaceuticals Back In The Spotlight
Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "Potential has a shelf life." - Margaret Atwood We last looked in on Xenon Pharmaceuticals (XENE) nearly nine months ago. In the summary of that article, the conclusion was that the company had some promising attributes and was worthy of a small 'watch item' via covered call positions. That turned out to be a profitable trade. Time for another potential round trip? We update the investment thesis on Xenon below. Seeking Alpha Company Overview: Xenon Pharmaceuticals is a clinical-stage biotech company focused on developing therapeutics to treat patients with neurological disorders. The company is based just outside of Vancouver, Canada. The stock trades just under $40.00 a share and sports an approximate market cap just north of $2.4 billion. August Company Presentation The company has several compounds in development as can be seen by the pipeline chart above. August Company Presentation The most important asset in development is a candidate called for the moment XEN1011. This is a next generation Kv7 potassium channel opener with potential applications in treating the focal onset seizures which occurs in epileptics as well as other potential neurological disorders. August Company Presentation A Phase 2b trial produced encouraging results in the fourth quarter of last year. The company then disclosed new, compelling efficacy data from that study 'X-TOLE' in June of this year. A Phase 2 study 'X-TOLE2' should initiate by the end of this year, followed shortly by a Phase 3 trial X-TOLE3. If successful, the company plans to submit a market application around this compound to treat epilepsy. August Company Presentation The compound is also in development for other neurological disorders. The company currently has a Phase 2 'X-NOVA' study underway examining XEN1101 in major depressive disorder or MDD. This trial in parallel with an investigator-led Phase 2 MDD study led by Xenon's collaborators at Mount Sinai. Topline results should be out in 2023. August Company Presentation XEN1101 is also now targeting primary generalized tonic clonic seizures or PGTCS. Management plans to initiate a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in PGTCS. This study should kick soon after initiation of the X-TOLE2 trial. August Company Presentation Another compound 'XEN496' is being developed to treat rare KCNQ2-DEE pediatric epilepsy. A Phase 3 study called EPIK, is ongoing to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. This trial should complete sometime in 2023. August Company Presentation Finally the company has licensed a selective Nav1.6 sodium channel inhibitor 'XEN901', now known as NBI-921352, to Neurocrine Biosciences (NBIX). That compound is in Phase 2 development for a couple of indications. As the result of this licensing agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties on any eventual commercialization. Analyst Commentary & Balance Sheet: Since second quarter results were posted on August 9th, five analyst firms including Needham and Wedbush have reissued Buy ratings on XENE. Price targets proffered ranged from $46 to $52 a share. On August 29th, Bank of America initiated the shares as a new Buy with a $45 a share price target. Here is the commentary from the bank's analyst at the time of that call.Seeking Alpha • Aug 29
Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Bank of America launched its coverage on clinical-stage biotech Xenon Pharmaceuticals Inc. (NASDAQ:XENE) with a Buy rating on Monday, arguing that the company’s mid-stage epilepsy candidate XEN1101 is poised to become a blockbuster drug. XEN1101 belongs to a class of drugs known as Kv7 potassium channel openers, and the drug is expected to undergo its Phase 3 program in H2 2022, XENE said this month. The analysts led by Jason M. Gerberry point to the blockbuster potential of XEN1101 ahead of important catalysts for its safety data, second confirmatory, and label expansion studies. The ease of use, novel mechanism of action, and strong efficacy differentiate XEN1101 from other anti-seizure medications, the team with a $48 per share target on XENE argued. Wall Street stands firmly behind the prospects of Xenon (XENE) with eleven Buy ratings and no Hold or Sell ratings.Seeking Alpha • Dec 13
Sizing Up Xenon Pharmaceuticals
Today, we look at Xenon Pharmaceuticals, a clinical-stage biotech concern with several products advancing in its pipeline. The stock recently has surged on top of positive mid-stage trial results. The shares have also seen some insider buying lately as well. A full investment analysis follows in the paragraphs below.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Xenon Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -383 | 84 | 0 |
| 31 Dec 25 | 8 | -346 | 80 | 0 |
| 30 Sep 25 | 8 | -306 | 76 | 0 |
| 30 Jun 25 | 8 | -278 | 73 | 0 |
| 31 Mar 25 | 8 | -251 | 73 | 0 |
| 31 Dec 24 | 0 | -234 | 69 | 0 |
| 30 Sep 24 | 0 | -213 | 64 | 0 |
| 30 Jun 24 | 0 | -199 | 60 | 0 |
| 31 Mar 24 | 0 | -189 | 52 | 0 |
| 31 Dec 23 | 0 | -182 | 47 | 0 |
| 30 Sep 23 | 0 | -175 | 42 | 0 |
| 30 Jun 23 | 0 | -164 | 38 | 0 |
| 31 Mar 23 | 1 | -147 | 36 | 0 |
| 31 Dec 22 | 9 | -125 | 33 | 0 |
| 30 Sep 22 | 13 | -113 | 31 | 0 |
| 30 Jun 22 | 21 | -91 | 27 | 0 |
| 31 Mar 22 | 23 | -83 | 25 | 0 |
| 31 Dec 21 | 18 | -77 | 22 | 0 |
| 30 Sep 21 | 20 | -66 | 18 | 0 |
| 30 Jun 21 | 18 | -59 | 17 | 0 |
| 31 Mar 21 | 29 | -37 | 14 | 0 |
| 31 Dec 20 | 32 | -29 | 13 | 0 |
| 30 Sep 20 | 30 | -28 | 13 | 0 |
| 30 Jun 20 | 27 | -28 | 13 | 0 |
| 31 Mar 20 | 14 | -38 | 12 | 0 |
| 31 Dec 19 | 7 | -42 | 11 | 0 |
| 30 Sep 19 | 4 | -39 | 10 | 0 |
| 30 Jun 19 | 0 | -44 | 9 | 0 |
| 31 Mar 19 | 0 | -42 | 9 | 0 |
| 31 Dec 18 | 0 | -34 | 8 | 0 |
| 30 Sep 18 | 0 | -34 | 8 | 0 |
| 30 Jun 18 | 0 | -27 | 8 | 0 |
| 31 Mar 18 | 0 | -27 | 7 | 0 |
| 31 Dec 17 | 0 | -31 | 7 | 0 |
| 30 Sep 17 | 1 | -29 | 7 | 4 |
| 30 Jun 17 | 1 | -29 | 7 | 10 |
| 31 Mar 17 | 1 | -27 | 7 | 15 |
| 31 Dec 16 | 2 | -23 | 7 | 19 |
| 30 Sep 16 | 5 | -21 | 7 | 18 |
| 30 Jun 16 | 9 | -17 | 6 | 16 |
| 31 Mar 16 | 12 | -10 | 5 | 14 |
| 31 Dec 15 | 16 | -16 | 10 | 12 |
| 30 Sep 15 | 17 | -2 | 10 | 11 |
| 30 Jun 15 | 26 | 5 | 10 | 9 |
Ingresos de calidad: XENE actualmente no es rentable.
Margen de beneficios creciente: XENE actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: XENE no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 34.7% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de XENE en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: XENE no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (54.5%).
Rentabilidad financiera
Alta ROE: XENE tiene una rentabilidad financiera negativa (-28.64%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/26 18:50 |
| Precio de las acciones al final del día | 2026/06/26 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Xenon Pharmaceuticals Inc. está cubierta por 25 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |